This is Archived Content

This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). Find the latest information on substance use, health, and NIDA research at

In accordance with the FY 2008 Congressional action and the NIH Fiscal Operations Plan for FY 08, the National Institute on Drug Abuse (NIDA) has established the following funding policy

New and Competing

NIDA will continue to use the:

New Investigators

  • NIDA is committed to supporting first-time R01 investigators (by NIH definition) and will maintain a comparable level to the average of the most recent five years. This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal payline.

Non-competing Continuations (Type 5)

  • Non-competing continuations (modular and non-modular) will be funded at 98% of committed levels, including co-funds. This policy does not apply to Fs, Ts, Ks, SBIR/STTRs, and R13s. Future year commitments will also be adjusted accordingly.
  • Awards previously issued in FY 2008 at reduced levels will be revised to restore funds to the level indicated above (see